Programmed cell death-1 pathway inhibitors in genitourinary malignancies: Specific side-effects and their management

Current Opinion in Urology

Volumn 26, Issue 6, 2016, Pages 548-555

  Tripathi, Abhishek ^a   Kaymakcalan, Marina D ^a   LeBoeuf, Nicole R ^b   Harshman, Lauren C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Checkpoint blockade; Immune related adverse events; Immunotherapy; Renal cell carcinoma; Urothelial carcinoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; ATEZOLIZUMAB; BILIRUBIN; CORTICOTROPIN; CREATININE; FOLLITROPIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; IPILIMUMAB; LUTEINIZING HORMONE; MYCOPHENOLATE MOFETIL; NIVOLUMAB; PEMBROLIZUMAB; PREDNISOLONE; PREDNISONE; PROGRAMMED DEATH 1 LIGAND 1; THYROTROPIN; PROGRAMMED DEATH 1 RECEPTOR;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ADRENAL INSUFFICIENCY; ADVERSE DRUG REACTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD PRESSURE; BULLOUS PEMPHIGOID; CANCER IMMUNOTHERAPY; CHILL; COLITIS; CORTICOSTEROID THERAPY; CORTICOTROPIN BLOOD LEVEL; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS; DIARRHEA; DRUG ERUPTION; DRUG FEVER; DYSPNEA; ECZEMA; ESOPHAGUS CANDIDIASIS; FATIGUE; FLUSHING; FOLLITROPIN BLOOD LEVEL; GINGIVITIS; GUILLAIN BARRE SYNDROME; HERPES SIMPLEX VIRUS; HUMAN; HYDRATION; HYPERTHYROIDISM; HYPOPHYSITIS; HYPOPIGMENTATION; HYPOTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INTERSTITIAL NEPHRITIS; INVASIVE ASPERGILLOSIS; KIDNEY CARCINOMA; LICHENOID ERUPTION; LIVER TOXICITY; LUTEINIZING HORMONE BLOOD LEVEL; MACULOPAPULAR RASH; MYELITIS; ORAL MUCOSITIS; PARANEOPLASTIC NEUROPATHY; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PREMEDICATION; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PUSTULE; REVIEW; SJOEGREN SYNDROME; SKIN EXFOLIATION; STRONGYLOIDIASIS; THYROTROPIN BLOOD LEVEL; TRANSITIONAL CELL CARCINOMA; UROGENITAL TRACT CANCER; URTICARIA; VARICELLA ZOSTER VIRUS; VIRUS REACTIVATION; VITILIGO; CELL DEATH; IMMUNOLOGY; URINARY TRACT TUMOR; UROGENITAL TRACT TUMOR;

CELL DEATH; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PROGRAMMED CELL DEATH 1 RECEPTOR; UROGENITAL NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 84981749597     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0000000000000332     Document Type: Review

References (52)

1. Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5:1365-1369.
2. Latchman YE, Liang SC, Wu Y, et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci USA 2004; 101:10691-10696.
3. Chambers CA, Kuhns MS, Egen JG, et al. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001; 19:565-594.
4. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1:405-413.
5. Kang MJ, Kim KM, Bae JS, et al. Tumor-infiltrating PD1-positive lymphocytes and FoxP3-positive regulatory T cells predict distant metastatic relapse and survival of clear cell renal cell carcinoma. Transl Oncol 2013; 6:282-289.
6. Nakanishi J, Wada Y, Matsumoto K, et al. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother 2007; 56:1173-1182.
7. Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 2004; 101:17174-17179.
8. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8:793-800.
9. Hodi FS. Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res 2007; 13:5238-5242.
10. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373:1803-1813.
11. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016; 387:1909-1920.
12. Atezolizumab prescribing information, Genentech, May 2016.
13. Tripathi A, Drake CG, Harshman LC. Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions. BioDrugs 2014; 28:513-526.
14. Bertsias GK, Nakou M, Choulaki C, et al. Genetic, immunologic, and im-munohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. Arthritis Rheum 2009; 60:207-218.
15. Zhernakova A, Eerligh P, Barrera P, et al. CTLA4 is differentially associated with autoimmune diseases in the Dutch population. Hum Genet 2005; 118:58-66.
16. Vaidya B, Pearce SH, Charlton S, et al. An association between the CTLA4 exon 1 polymorphism and early rheumatoid arthritis with autoimmune en-docrinopathies. Rheumatology (Oxford) 2002; 41:180-183.
17. Prokunina L, Castillejo-Lopez C, Oberg F, et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 2002; 32:666-669.
18. Ueda H, Howson JM, Esposito L, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423:506-511.
19. Kaehler KC, Piel S, Livingstone E, et al. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol 2010; 37:485-498.
20. Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 2015; 33:3193-3198.
21. Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis. J Clin Oncol 2015; 33:. (suppl; abstr 9018).
22. Opdivo prescribing information, http://packageinserts.bms.com/pi/pi-opdi-vo.pdf, Bristol-Myers Squibb, January 2016.
23. Nivolumab, immune mediated adverse reactions management guide.
24. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373:123-135.
25. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16:375-384.
26. Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2015; 33:. (suppl; abstr 4516).
27. Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007; 30:825-830.
28. CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2015; 33:. (suppl; abstr TPS4578).
29. Belum VR, Benhuri B, Postow MA, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 2016; 60:12-25.
30. Pintova S, Sidhu H, Friedlander PA, et al. Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy. Melanoma Res 2013; 23:498-501.
31. Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book 2015; 76-83.
32. Jour G, Glitza IC, Ellis RM, et al. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions. J Cutan Pathol 2016; 43:688-696.
33. Chia PL, John T. Severe psoriasis flare after anti-programmed death ligand 1 (PD-L1) therapy for metastatic non-small cell lung cancer (NSCLC). J Im-munother 2016; 39:202-204.
34. Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2015; 26:2375-2391.
35. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolu-mab, supplementary data. J Clin Oncol 2014; 32:1020-1030.
36. Hwang SJ, Carlos G, Wakade D, et al. Cutaneous adverse events (AEs) of antiprogrammed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol 2016; 74:455-461; e1.
37. Joseph RW, Cappel M, Goedjen B, et al. Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy. Cancer Immunol Res 2015; 3:18-22.
38. Common Terminology Criteria for Adverse Events (CTCAE), version 4.0; May 28, 2009.
39. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2014; 32:5s. (suppl; abstr 4504).
40. American dietetic association Crohn's-Colitis diet; http://www.uccs.edu/Documents/peakfood/hlthTopics/Crohns Disease Nutrition.pdf.
41. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with suni-tinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2014; 32:5s. (suppl; abstr 5010).
42. Nishino M, Sholl LM, Hodi FS, et al. Anti-PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med 2015; 373:288-290.
43. Orlov S, Salari F, Kashat L, et al. Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies. J Clin Endocrinol Metab 2015; 100:1738-1741.
44. Corsello SM, Barnabei A, Marchetti P, et al. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 2013; 98:1361-1375.
45. Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann Oncol 2011; 22:991-993.
46. Maur M, Tomasello C, Frassoldati A, et al. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol 2012; 30:e76-e78.
47. Liao B, Shroff S, Kamiya-Matsuoka C, et al. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 2014; 16:589-593.
48. Bot I, Blank CU, Boogerd W, et al. Neurological immune-related adverse events of ipilimumab. Pract Neurol 2013; 13:278-280.
49. Salam S, Lavin T, Turan A. Limbic encephalitis following immunotherapy against metastatic malignant melanoma. BMJ Case Rep 2016; 2016:.
50. Shirali AC, Perazella MA, Gettinger S. Association of acute interstitial ne-phritis with programmed cell death 1 inhibitor therapy in lung cancer patients. Am J Kidney Dis 2016; doi: 10.1053/j.ajkd.2016.02.057. [Epub ahead of print]
51. Opportunistic infections in patients receiving immunotherapy with CTLA-4, PD-1 and PD-L1 blockers for treatment of metastatic melanoma. ID week 2015, Abstract 1214.
52. Kyi C, Hellmann MD, Wolchok JD, et al. Opportunistic infections in patients treated with immunotherapy for cancer. J Immunother Cancer 2014; 2:19.